HealthInsights

Cancer has long been a formidable adversary in the field of medicine, affecting millions of lives worldwide. However, in recent years, revolutionary advancements in cancer treatment have brought hope to patients and healthcare professionals alike. One such breakthrough is the emergence of ENHERTU , a cutting-edge therapy with the potential to transform cancer management. In this blog, we will explore ENHERTU's journey in cancer treatment and its impact on various types of cancers. How is it different from other chemotherapy drugs? ENHERTU , developed by Daiichi Sankyo and AstraZeneca, belongs to a novel class of drugs known as antibody-drug conjugates (ADCs). Unlike traditional chemotherapy, which indiscriminately attacks both cancerous and healthy cells, ENHERTU is designed to deliver its payload selectively to cancer cells, minimizing damage to surrounding tissues. This targeted approach reduces the severity of side effects, enhancing the overall quality of life for patients duri...

Antibody-drug conjugates have emerged as a revolutionary class of therapies in the field of oncology. By combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs, Antibody-drug conjugates offer a targeted approach to cancer treatment. In this blog, we will provide an overview of the current and future treatment landscape of Antibody-drug conjugates in oncology, exploring their mechanism of action and potential applications. Understanding Antibody-Drug Conjugates: Antibody-drug conjugates are designed to deliver a cytotoxic drug directly to cancer cells by attaching it to a monoclonal antibody. The antibody recognizes and binds to specific markers on the cancer cells, allowing the drug to be selectively delivered to the tumor site. This targeted approach reduces damage to healthy cells and enhances treatment efficacy. Current Marketed Antibody-drug conjugates in Oncology: Several Antibody-drug conjugates have gained approval and are making a significant im...